Moteur de recherche d’entreprises européennes

Financement de l’UE (15,6 M €) : Phage personnalisé contre E. coli avec antibiotique IV pour éliminer les biofilms stables dans les infections urinaires Hor 29/05/2026 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Phage personnalisé contre E. coli avec antibiotique IV pour éliminer les biofilms stables dans les infections urinaires

P-PEAKS UTI is a multicenter, intercontinental Phase II randomized controlled trial evaluating the safety, efficacy, and feasibility of personalized bacteriophage therapy in combination with intravenous beta-lactam antibiotics for the secondary prevention of recurrent urinary tract infections (rUTIs) caused by Escherichia coli in female patients . The study will recruit 216 participants across 9 clinical sites, including high-risk renal transplant recipients. Phage therapy or placebo will be administered via oral (day 1 and 2), bladder instillation (day 1), and topical/vaginal routes all over 5 days. Both arms will receive a single dose of IV antibiotic on day 2 to enhance bacterial clearance and biofilm disruption. This combination strategy leverages potential synergy between phages and antibiotics, aiming to reduce recurrence rates and antibiotic use. The project integrates AI-based phage-host prediction, GMP and Magistral phage production, and standardized susceptibility testing aligned with EUCAST guidelines. It investigates phage immunogenicity, microbiome dynamics, and pharmacokinetics/pharmacodynamics to inform future personalized antimicrobial strategies. P-PEAKS UTI also performs health economic analysis to quantify cost-effectiveness of phage therapy in urinary tract infections compared to standard antibiotic treatment and engages patients to address stigma and acceptability of phage therapy. It contributes to regulatory science by generating quantifiable, replicable data to support future market authorization of phage therapies and informs policy through collaboration with EMA and national agencies. In the longer term, we aim to deliver an improved, effective and meaningful solution for the prevention of recurrent UTIs in female patients improving their health outcomes and quality of life. This will also strengthen healthcare systems’ capacity to combat antimicrobial resistance and empower citizens with knowledge-based alternatives to antibiotics.


Assistance Publique Hopitaux de Paris 473 271 €
Azienda Ospedaliero Universitaria Pisana 371 006 €
Baylor College OF Medicine 884 132 €
Europaischer Nierenpatientenverband 146 188 €
Fundacion Publica Galega de Investigacion Biomedica Inibic 406 949 €
Hadassah Medical Organization 777 160 €
Lunds Universitet 145 375 €
Mayo Clinic 678 142 €
Micron Research Ltd. 3 134 900 €
Patrimoine de l'Ecole Royale Militaire - Vermogen Van de Koninklijke Militaire School 602 628 €
Philipps Universitaet Marburg 218 378 €
Qeen Biotechnologies Inc. 1 244 513 €
SA Tartu Ulikooli Kliinikum 462 829 €
Tartu Ulikool 959 886 €
THE Hebrew University OF Jerusalem 772 822 €
THE Regents OF THE University OF California 693 859 €
Unity Health Toronto 2 428 962 €
Universite Laval 144 071 €
University College London 974 895 €
University OF Calgary 77 567 €

https://cordis.europa.eu/project/id/101289070

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.